Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.14207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Matthew D Howe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Butler Hospital Memory & Aging Program, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Biomarkers, Alzheimer Disease, Magnetic Resonance Imaging. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lumosity; Lundbeck; Merck & Co., Inc., NIA NIH HHS, CIHR.
Abstract (Originalsprache)
INTRODUCTION The relationship between cerebrovascular disease (CVD) and amyloid beta (Aβ) in Alzheimer's disease (AD) is understudied. We hypothesized that magnetic resonance imaging (MRI)–based CVD biomarkers—including cerebral microbleeds (CMBs), lacunar infarction, and white matter hyperintensities (WMHs)—would correlate with Aβ positivity on positron emission tomography (Aβ‐PET). METHODS We cross‐sectionally analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI, N = 1352). Logistic regression was used to calculate odds ratios (ORs), with Aβ‐PET positivity as the standard‐of‐truth. RESULTS Following adjustment, WMHs (OR = 1.25) and superficial CMBs (OR = 1.45) remained positively associated with Aβ‐PET positivity ( p < 0.001). Deep CMBs and lacunes exhibited a varied relationship with Aβ‐PET in cognitive subgroups. The combined diagnostic model, which included CVD biomarkers and other accessible measures, significantly predicted Aβ‐PET (pseudo‐R 2 = 0.41). DISCUSSION The study highlights the translational value of CVD biomarkers in diagnosing AD, and underscores the need for more research on their inclusion in diagnostic criteria. ClinicalTrials.gov : ADNI‐2 (NCT01231971), ADNI‐3 (NCT02854033). Highlights Cerebrovascular biomarkers linked to amyloid beta (Aβ) in Alzheimer's disease (AD). White matter hyperintensities and cerebral microbleeds reliably predict Aβ‐PET positivity. Relationships with Aβ‐PET vary by cognitive stage. Novel accessible model predicts Aβ‐PET status. Study supports multimodal diagnostic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Butler Hospital Memory & Aging Program, Providence, Rhode Island, USA.
- Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, USA.
- University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Center of Innovation in Long-Term Services and Supports, Providence VA Medical Center, Providence, Rhode Island, USA.
- Department of Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
ORCID-Profile: Matthew D Howe
Förderung
- Lumosity; Lundbeck; Merck & Co., Inc.
- NIA NIH HHS
- CIHR
- GE Healthcare
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Transition Therapeutics
- NIBIB NIH HHS
- F. Hoffmann-La Roche Ltd
Zitieren
APA
Howe, M. D., Caruso, M. R., Manoochehri, M., Kunicki, Z. J., Emrani, S., Rudolph, J. L., Huey, E. D., Salloway, S. P., Oh, H., & Alzheimer's Disease Neuroimaging Initiative (2024). Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14207
Vancouver
Howe MD, Caruso MR, Manoochehri M, Kunicki ZJ, Emrani S, Rudolph JL, et al. Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14207
BibTeX
@article{Howe2024,
author = {Howe, Matthew D and Caruso, Megan R and Manoochehri, Masood and Kunicki, Zachary J and Emrani, Sheina and Rudolph, James L and Huey, Edward D and Salloway, Stephen P and Oh, Hwamee and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.14207}
}
EUVIMED